EUCTR2015-004828-66-ES进行中（未招募）1 期
A phase IIa clinical trial to evaluate the safety and efficacy of osirmertinib (AZD9291) in first-line patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer and concomitant EGFR T790M mutation at time of diagnosis (AZENT study) - AZENT
Medica Scientia Innovation Research (MedSIR ARO)0 个研究点目标入组 73 人开始时间: 2016年5月18日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 73
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion criteria
- •1.Patient aged 18 years or older.
- •2.Patients with histological confirmation of locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with an activating EGFR mutation and concomitant T790M mutation who are not candidates for local curative treatment.
- •3.Patients with a M1a stage according to the TNM version 7 including M1a (malignant effusion) or M1b (distant metastasis), or locally advanced disease for which there is no curative treatment (including patients who progress after chemoradiotherapy in stage III disease).
- •4.Patients with a EGFR deletion or mutation in exon 19, exon 21 (L858R, L861Q) or exon 18 (G719X) and concomitant T790M mutation before treatment confirmed centrally.
- •5.ECOG (Eastern Cooperative Oncology Group) performance status less than or equal to 2.
- •6.Existence of measurable or evaluable disease (as per RECIST 1.1 criteria). Patients with asymptomatic and stable brain metastases are eligible for the study.
- •7.Possibility of obtaining sufficient tissue sample, via a biopsy or surgical resection of the primary tumor or metastatic tumor tissue, within the 60 days prior to study entry.
- •8.Life expectancy =12 weeks.
- •9.Adequate hematologic function: Absolute neutrophil count (ANC) > 1.5 x 109/L, platelet count > 100.0 x109/L and hemoglobin > 9.0 g/dL (> 6.2 mmol/L).
- •10.Adequate coagulation: INR = 1.5.
- •11.Adequate liver function: Total bilirubin < 1.5 × ULN, ALT and/or AST < 2.5 × ULN, alkaline phosphatase < 5 ULN, except in the presence of single bone metastases and in absence of any liver disorders.
- •12.Adequate renal function: Calculated creatinine clearance > 50 mL/min (Cockroft-Gault) and proteinuria < 2+ (dipstick).
- •13.Capacity to swallow, patient capable of completing treatment and accessible, ensuring proper follow-up.
- •14.Patients able to complete study and within geographical proximity allowing for adequate follow-up.
- •15.Resolution of all acute toxic effects of any previous anti-cancer therapy (which can only be adjuvant or neoadjuvant) or previous surgical interventions not exceeding grade ? 1 according to the NCI CTCAE version 4.0 (except for alopecia or other side effects that the investigator does not consider to be a risk to patient safety).
- •16.All men or women of childbearing potential must use a contraception method during the study treatment and for at least 12 months after the last dose of the study drug. Sexually active men and women of childbearing potential who are unwilling to use a contraception method are not eligible for the study.
- •17.The written informed consent (IC) must be signed and dated by the patient and the investigator before any study intervention takes place.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 73
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 73
排除标准
- •Any patient meeting ANY of the following criteria will be excluded from the study:
- •1.Locally advanced lung cancer candidate for curative treatment through radical surgery and/or radio(chemo)therapy.
- •2.Patients diagnosed with another lung cancer subtype, patients with mixed NSCLC with predominantly squamous cell cancer, or with any small-cell lung cancer component.
- •3.Patients with a EGFR deletion or mutation in exon 19, exon 21 (L858R, L861Q) or exon 18 (G719X) and concomitant T790M mutation before treatment that have not been confirmed centrally.
- •4.Patients who have received prior antineoplastic treatment for advanced disease.
- •5.Second active neoplasia; e.g. patients diagnosed with a potentially lethal cancer for which they may be receiving treatment (but are not obliged to do so).
- •6.Patients with just one measurable or evaluable tumor lesion that has been resected or irradiated prior to their enrollment in the study.
- •7.Medical history of Interstitial Lung Disease (ILD) induced by drugs, radiation pneumonitis requiring steroid treatment or any evidence of clinically active ILD.
- •8.Any of the following criteria:
- •Corrected QT Interval (QTc) >470 msec, obtained from 3 ECGs at rest, using the QTc value determined according to the clinical screening ECG machine.
- •Any clinically significant abnormality in ECG rhythm, conduction or morphology at rest.
- •Any factor that increases the risk of QTc prolongation or risk of irregular heartbeat or sudden inexplicable death under the age of 40 in first-degree relatives or any concomitant medications that prolong the QT interval.
- •9.Uncontrolled, active or symptomatic metastases of CNS, carcinomatous meningitis or leptomeningeal disease indicated by known clinical symptoms, cerebral edema and/or progressive neoplasia. Patients with history of CNS metastasis or compression of the spinal cord are eligible if they have received local final treatment (e.g., radiotherapy, stereotactic surgery) and if they have remained clinically stable without using anticonvulsants and corticosteroids for a minimum of 4 weeks prior to the first day of study treatment.
- •10.Refractory nauseas and vomiting, chronic gastrointestinal disease, inability to swallow study drug or significant intestinal resection that restricts the adequate absorption of osimertinib (AZD9291).
- •11.Patients who have had a surgical procedure unrelated to the study within 7 days prior to the administration of the drug or a significant traumatic lesion during the 4 weeks prior to starting the administration of the study drug, patients who have not recovered from the side effects of any major surgery or patients who might need major surgery during the course of the study.
- •12.Pregnant or breastfeeding women. Women of childbearing potential, including women who had their last menstrual period within the last two years, must have a negative serum or urine pregnancy test in the 7 days prior to the start of the treatment.
- •13.Patients who are not willing to use an adequate contraception method until 12 months after the last dose of study treatment.
- •14.Patients with a serious concomitant systemic disorder (e.g., active infection, including HIV or heart disease) that is incompatible with the study (in the opinion of the investigator), history of bleeding diathesis or anticoagulant therapy (the use of low molecular weight heparin is permitted provided that it is used for prophylaxis).
- •15.Inability to swallow tablets.
- •16.Patients with a history of
研究者
相似试验
招募中
不适用
A phase 1/2a clinical trial to evaluate the safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cell clusters in patients with critical limb ischemiaDiseases of the circulatory systemKCT0006001S.Biomedics20
招募中
1 期
A trial to evaluate safety and characteristics of a substance for treatment of chronic hepatitisChronic hepatitis BMedDRA version: 20.1Level: PTClassification code: 10008910Term: Chronic hepatitis B Class: 100000004862CTIS2023-503880-40-00Suzhou Ribo Life Science Co. Ltd.48
进行中（未招募）
1 期
VAC079; a study to the assess the safety and efficacy of the malaria vaccine PvDBPII in Matrix M1EUCTR2019-002872-14-GBniversity of Oxford / Clinical Trials and Research Governance24
进行中（未招募）
1 期
A study to assess the new malaria vaccine RH5.1/AS01EUCTR2016-001718-31-GBniversity of Oxford, CTRG84
尚未招募
1 期
A preliminary study for testing a new drug to kidney stones treatmentnephrolithiasisN20.9C12.777.419.600RBR-6cf4xhHospital das Clínicas da Faculdade de Medicina de Ribeirão Preto